GPRC5D and Miyoshi myopathy: In a case report, siltuximab alone successfully managed a grade 2 ICANS patient who received talquetamab, a T cell redirecting bispecific antibody that targets G protein-coupled receptor, class C group 5 member D (GPRC5D) on MM cells and CD3 on T cells (34).